Mass Device
Day Zero Diagnostics raises $8.2M from CARB-X
October 24 2022

Day Zero Diagnostics receives an $8.2 million award in optional stage funding from CARB-X.

Read More
bioworld medtech
Day Zero receives $8.2M to speed development of infectious disease diagnostic
October 21 2022

Day Zero receives $8.2M from CARB-X to speed development of infectious disease diagnostics.

Read More
genome web
Day Zero Diagnostics secures additional $8.2M from CARB-X
October 20 2022

Additional CARB-X funding supports the transition into product development of the firm's whole-genome sequencing and machine learning-based approach to antimicrobial resistance profiling.

Read More
AMR Insights - EADA 2021
Day Zero Diagnostics at EADA 2021: A better way to diagnose and treat sepsis is on the horizon
January 5 2022

Learn how we are predicting antimicrobial susceptibility directly from blood using whole-genome sequencing with Day Zero Diagnostic's Scientific Co-founder, Melis Anahtar, MD, Phd.

Read More
Diagnosis On Day Zero
January 4 2022

Day Zero Diagnostics was featured in AACC's December issue of "Clinical Laboratory News", highlighting our work around whole genome sequencing and machine learning for rapid diagnosis of infections directly from blood.

Read More
Day Zero Diagnostics wins 2021 AACC disruptive tech award
September 29 2021

Day Zero is proud to have been selected for the Disruptive Technology Award from AACC

Read More